Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF)

Ryan P Coyle; Mary Morrow; Sarah C Mann; Vincent Mainella; Samuel L Ellis; Stefanie Schwab; Corwin Coppinger; Nicholas Barker; Lucas Ellison; Jia-Hua Zheng; Subhi Al Zuabi; Pamela E Alpert; Tony C Carnes; D Eric Buffkin Jr; Peter R Chai; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Kristina M Brooks; Peter L Anderson; Jose R Castillo-Mancilla

doi:10.1093/cid/ciae212

Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF)

Clin Infect Dis. 2024 Apr 18:ciae212. doi: 10.1093/cid/ciae212. Online ahead of print.

Authors

Ryan P Coyle¹, Mary Morrow², Sarah C Mann³, Vincent Mainella¹, Samuel L Ellis⁴, Stefanie Schwab¹, Corwin Coppinger¹, Nicholas Barker¹, Lucas Ellison¹, Jia-Hua Zheng¹, Subhi Al Zuabi¹, Pamela E Alpert⁵, Tony C Carnes⁵, D Eric Buffkin Jr⁵, Peter R Chai^{6

7

8}, Lane R Bushman¹, Jennifer J Kiser^{1

9}, Samantha MaWhinney², Kristina M Brooks¹, Peter L Anderson¹, Jose R Castillo-Mancilla^{3

10}

Affiliations

¹ Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
² Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
³ Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
⁴ Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
⁵ etectRx, Gainesville, FL, USA.
⁶ Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷ Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁸ The Fenway Institute, Boston, MA, USA.
⁹ Merck & Co., Inc., Rahway, NJ, USA.
¹⁰ ViiV Healthcare, Durham, NC, USA.

PMID: 38636950
DOI: 10.1093/cid/ciae212

Abstract

Background: QUANTI-TAF aimed to establish tenofovir-diphosphate/emtricitabine-triphosphate (TFV-DP/FTC-TP) adherence benchmarks in dried blood spots (DBS) for persons with HIV (PWH) receiving tenofovir alafenamide/emtricitabine (TAF/FTC)-based antiretroviral therapy (ART).

Methods: During a 16-week pharmacokinetic study, PWH received TAF/FTC-based ART co-encapsulated with an ingestible sensor to directly measure cumulative (enrollment to final visit) and 10-day adherence. At monthly visits, intraerythrocytic concentrations of TAF/FTC anabolites (TFV-DP/FTC-TP) in DBS were quantified by LC-MS/MS and summarized at steady-state (week 12 or 16) as median (IQR). Linear mixed-effects models evaluated factors associated with TFV-DP/FTC-TP.

Results: 84 participants (86% male, 11% female, and 4% transgender), predominantly receiving bictegravir/TAF/FTC (73%) enrolled. 92% completed week 12 or 16 (94% receiving unboosted ART). TFV-DP for <85% (7/72), ≥85%-<95% (9/72), and ≥95% (56/72) cumulative adherence was 2696 (2039-4108), 3117 (2332-3339), and 3344 (2605-4293) fmol/punches. All participants with ≥85% cumulative adherence had TFV-DP ≥1800 fmol/punches. Adjusting for cumulative adherence, TFV-DP was higher with boosted ART, lower BMI, and in non-Blacks. FTC-TP for <85% (14/77), ≥85%-<95% (6/77), and ≥95% (57/77) 10-day adherence was 3.52 (2.64-4.48), 4.58 (4.39-5.06), and 4.96 (4.21-6.26) pmol/punches. All participants with ≥85% 10-day adherence had FTC-TP ≥2.5 pmol/punches. Low-level viremia (HIV-1 RNA ≥20-<200 copies/mL) occurred at 60/335 (18%) visits in 33/84 (39%) participants (range: 20-149 copies/mL), with similar TFV-DP (3177 [2494-4149] fmol/punches) compared with HIV-1 RNA <20 copies/mL visits (3279 [2580-4407] fmol/punches).

Conclusions: We propose PK-based TFV-DP (≥1800 fmol/punches)/FTC-TP (≥2.5 pmol/punches) benchmarks in DBS for PWH receiving unboosted TAF/FTC-based ART with ≥85% adherence. In the setting of high adherence, low-level viremia was common.

Keywords: adherence benchmarks; dried blood spots; low-level viremia; tenofovir alafenamide; tenofovir-diphosphate.

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].